# A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

> **NCT07678684** · PHASE2 · RECRUITING · sponsor: **HighField Biopharmaceuticals Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Glioma
- Adult

## Interventions

- **DRUG:** HF1K16

## Key facts

- **NCT ID:** NCT07678684
- **Lead sponsor:** HighField Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678684, "A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*